The global precocious puberty treatment market is on a remarkable growth trajectory, with an estimated valuation of USD 1,716.43 million in 2023, projected to nearly double to USD 3,650.66 million by 2033, reflecting a robust CAGR of 7.8% during the forecast period.
Key Drivers of Market Growth:
- Regulatory Approvals Propelling Market Expansion:
Industry players are increasingly focusing on securing product approvals from regulatory bodies such as the United States Food and Drug Administration (FDA). This strategy is expected to significantly drive market growth. For instance, in May 2020, Tolmar Pharmaceuticals, Inc. obtained FDA approval for its New Drug Application for FENSOLVI® (leuprolide acetate), an injectable suspension for treating pediatric patients aged two years and older with precocious puberty.
- Strategic Collaborations Strengthening Market Position:
Companies are adopting inorganic growth strategies, such as partnerships, mergers, and distribution agreements, to enhance their market presence. A notable example is the January 2016 agreement between Debiopharm International SA and Arbor Pharmaceuticals for the exclusive distribution of triptorelin 22.5 mg for treating Central Precocious Puberty.
- Innovative Research and Development Efforts:
Research activities surrounding triptorelin for various therapeutic applications are accelerating market growth. Triptorelin’s high efficacy and tolerability in suppressing gonadotropin secretion have increased its adoption for treating both precocious puberty and prostate cancer.
- Geographical Expansion and Product Availability:
Key players are expanding their product portfolios into new geographical regions. In October 2017, Arbor Pharmaceuticals and Debiopharm International SA launched Triptodur® (triptorelin) in the United States, offering a critical treatment option for pediatric patients diagnosed with precocious puberty.
- Reimbursement Policies Enhancing Accessibility:
Financial support for precocious puberty treatments through Medicaid programs is expected to create lucrative growth opportunities, making these treatments more accessible to patients worldwide.
Future Outlook
The precocious puberty treatment market is poised for sustained growth, driven by innovative product developments, strategic partnerships, and an increasing focus on regulatory compliance. With key players investing in R&D and expanding their geographical reach, the market is well-positioned to meet the growing demand for effective treatment options.
Key Takeaways from the Market Study:
- North America is expected to dominate the industry while reaching market share of around 46.7% by end of the forecast period.
- The market in East Asia is projected to account for 25% market share by end of the projected period.
- By drug class, ‘triptorelin’ is projected to account for 62% market share by end of the forecast period.
- Hospitals are expected to dominate the market by distribution channel, with a market share of 58% by 2033.
“Increasing rate of product approvals, surging growth in mergers and acquisitions between companies, and development of new drugs will increase the product demand for treatment of precocious puberty,” comments an FMI analyst.
Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trends!
Competitive Landscape:
The precocious puberty treatment market is extremely competitive and consists of various key market players. These players are developing novel delivery systems for treating precocious puberty. This is anticipated to fuel precocious puberty treatment market. The key players in this market are: Teva Pharmaceutical Industries Ltd, AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc, Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, Sun Pharmaceutical Industries Limited, Sanofi
Key industry players are inclined on adoption of inorganic growth strategies like acquisition, partnerships, and collaboration in order to bolster their product portfolio. This is expected to propel the global precocious puberty treatment market.
- In June, 2020, Ipsen Pharma undergone strategic partnership with Debiopharm for Decapeptyl (triptorelin) for another 15 years. Decapeptyl (triptorelin) is used for treating central precocious puberty in children. This strategic merger helped the company to maintain a continuous product access to patients.
- In March 2022, Accord BioPharma, the United States special division of Intas Pharmaceuticals, Ltd. declared the United States launch of CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of progressive prostate cancer in adults.In February 2022, BDR Pharmaceuticals revealed its brand ENZALUTAMIDE, an antiandrogen in 160mg with brand name BDENZA for treatment of Prostate Cancer patients.
- In January 2019, Debiopharm group informed about an agreement with Allergan to begin a transition process for Trelstar (Triptorelin pamoate) intended to lead to new licensees taking over the commercialization of Trelstar in the United States and Canada and the termination of Allergan’s partnership with Debiopharm for strategic reasons.
Key Segments Profiled in the Precocious Puberty Treatment Industry Survey:
By Drug Class:
- Leuprorelin
- Histrein
- Triptorelin
- Nafarelin
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐅𝐌𝐈’𝐬 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐎𝐧𝐠𝐨𝐢𝐧𝐠 𝐂𝐨𝐯𝐞𝐫𝐚𝐠𝐞 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐃𝐨𝐦𝐚𝐢𝐧:
Non-Invasive Respiratory Monitoring Industry
At-Home Cancer Testing Industry
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube